From trial-and-error to inverse design: how AI is redefining drug delivery systems

Read full text
Authors: Sofía Blas-Gómez, Carlos Alonso-Moreno, Alberto Ocaña, Iván Bravo
Cited by: 1
References: 37

Abstract

AI is transforming drug delivery system (DDS) design by enabling predictive modeling and inverse design strategies. Recent advances integrating machine learning, deep learning and physics-informed approaches have improved the ability to capture complex formulation-performance relationships. This review provides a structured overview of AI methodologies in DDS, compares their strengths and limitations, and discusses their integration into pharmaceutical pipelines. Key challenges, including data heterogeneity, limited generalizability, model interpretability and regulatory validation, are critically assessed as barriers to clinical translation of AI-driven DDS design.

Fields of Study & Subjects

Computational Drug Discovery Methods Drug Solubulity and Delivery Systems Machine Learning in Materials Science

Publication details

Journal / source
Drug Discovery Today
Publisher
Elsevier BV
Volume
31
Issue
4
Pages
104725–104725
Publication date
18 June 2026
Language
EN